IMUX Stock Overview
About the company
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Snowflake Analysis
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Immunic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.67 |
| 52 Week High | US$12.64 |
| 52 Week Low | US$1.11 |
| Beta | 1.7 |
| 1 Month Change | -16.92% |
| 3 Month Change | 41.53% |
| 1 Year Change | -85.16% |
| 3 Year Change | -68.25% |
| 5 Year Change | n/a |
| Change since IPO | -93.08% |
Recent News & Updates
Recent updates
Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo
Oct 20Immunic stock gains on $60M oversubscribed PIPE financing
Oct 10Immunic GAAP EPS of -$0.72 in-line
Aug 04Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely
Jul 27
Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?
Apr 13Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?
Dec 24Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation
Aug 13We're Hopeful That Immunic (NASDAQ:IMUX) Will Use Its Cash Wisely
May 10Immunic EPS misses by $0.95
May 06Immunic EPS misses by $0.07
Nov 05Enrollment underway in Immunic's Phase 2 part of IMU-838 study in COVID-19
Nov 02Immunic (IMUX) Investor Presentation - Slideshow
Oct 31Shareholder Returns
| IMUX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.6% | 1.0% | 2.1% |
| 1Y | -85.2% | -1.2% | -12.8% |
Return vs Industry: IMUX underperformed the US Biotechs industry which returned -3.3% over the past year.
Return vs Market: IMUX underperformed the US Market which returned -13.7% over the past year.
Price Volatility
| IMUX volatility | |
|---|---|
| IMUX Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: IMUX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: IMUX's weekly volatility has decreased from 21% to 14% over the past year, but is still higher than 75% of US stocks.
Immunic, Inc. Fundamentals Summary
| IMUX fundamental statistics | |
|---|---|
| Market Cap | US$74.15m |
| Earnings (TTM) | -US$120.41m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs IMUX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMUX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$120.41m |
| Earnings | -US$120.41m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.71 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMUX perform over the long term?
See historical performance and comparison